Antibe Therapeutics Announces Grant of Restricted Share Units
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) announces that it has granted restricted share
units (“RSUs”) pursuant to the Company’s RSU plan that was adopted at the most recent annual shareholder’s meeting on June 25,
2018.
Walt Macnee, the Chair of Antibe, commented, “The past year has been tremendously successful for Antibe. Our lead drug, ATB-346,
delivered unequivocal proof-of-concept human data in the Phase 2B GI safety study. This outcome validated the commercial potential
of Antibe’s novel drug development pipeline and its hydrogen sulfide technology. Moreover, we expect the current momentum to grow
significantly, as we will soon commence the Phase 2 dose-ranging, efficacy study for ATB-346, focus on Phase 3 development,
accelerate our business development efforts and advance and expand the rest of our drug development pipeline. Accordingly, it’s my
pleasure to award these RSUs to Antibe’s team, of which the vesting of a large portion will be contingent on the achievement of key
value-driving milestones.”
It is the Board’s standard practice to grant equity compensation awards on an annual basis. However, the vigorous clinical and
business development activities have precluded the Company from making any new issuances in the past 18 months. A total of
17,700,000 RSUs were granted to directors, officers, employees and consultants. The vesting of 50% - 67% of the RSUs granted to key
executives will be subject to the achievement of specific performance goals that are designed to reflect the successful execution
of the Company’s business plan and strategy. In addition, all RSUs are subject to time-based vesting; one third (1/3) of the RSUs
granted will vest on each of the first, second and third anniversaries of the date hereof. In the case of RSUs granted to special
advisor consultants, one twelfth (1/12) of the RSUs will vest on the grant date, and an additional 1/12th of the RSUs
will vest on the last day of each calendar quarter thereafter over three years.
In addition, the Company has granted BND Projects Inc. 90,000 options for investor relations services. Each option has an
exercise price of $0.35, being the 5-day volume weighted average price of Antibe’s shares, vests quarterly starting on the date of
the grant, and will expire October 3, 2021.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing
molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a
safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent
global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products
servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of
knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries,
operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.
www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing
and development of drugs. Any statements contained herein that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect",
"intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that
could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release.
Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not
limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its
inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical
device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update
the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable
law.
Antibe Therapeutics Inc.
Dan Legault, (416) 473 4095
Chief Executive Officer
dan.legault@antibethera.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181003005772/en/